Thermo Fisher Launches Biologics Platform to Speed Up Drug Development
Event summary
- Thermo Fisher Scientific launched the Gibco™ CHOvantage™ GS Cell Line Development (CLD) Kit, an integrated platform for biologics development.
- The kit enables protein titers of ≥7 g/L in fed-batch cultures and stable clone selection within 14 weeks.
- The platform includes royalty-free clinical-stage licensing to reduce costs and streamline market entry.
- BioFactura was a key pre-launch testing partner for the new platform.
The big picture
Thermo Fisher's launch of the CHOvantage GS CLD Kit comes as the biologics pipeline expands, driven by increasing demand for protein therapeutics and biosimilars. The platform addresses key industry challenges—shortening time to clinic, improving manufacturing consistency, and controlling costs—while navigating stricter regulatory standards. With annual revenue exceeding $40 billion, Thermo Fisher is leveraging its scale to simplify and standardize biologics development workflows.
What we're watching
- Market Adoption
- How quickly biologics developers will adopt the CHOvantage GS CLD Kit, given its promise of accelerated timelines and cost savings.
- Regulatory Confidence
- Whether the platform's integrated approach will enhance regulatory compliance and streamline approval processes for new therapies.
- Competitive Response
- The pace at which competitors will respond with similar or improved technologies to capture market share in biologics development.
Related topics